Murata, M.; Sugimoto, M.; Mizuno, H.; Kanno, T.; Satoh, K.
Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. J. Clin. Med. 2020, 9, 543.
https://doi.org/10.3390/jcm9020543
AMA Style
Murata M, Sugimoto M, Mizuno H, Kanno T, Satoh K.
Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. Journal of Clinical Medicine. 2020; 9(2):543.
https://doi.org/10.3390/jcm9020543
Chicago/Turabian Style
Murata, Masaki, Mitsushige Sugimoto, Hitomi Mizuno, Takeshi Kanno, and Kiichi Satoh.
2020. "Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis" Journal of Clinical Medicine 9, no. 2: 543.
https://doi.org/10.3390/jcm9020543
APA Style
Murata, M., Sugimoto, M., Mizuno, H., Kanno, T., & Satoh, K.
(2020). Clarithromycin Versus Metronidazole in First-Line Helicobacter Pylori Triple Eradication Therapy Based on Resistance to Antimicrobial Agents: Meta-Analysis. Journal of Clinical Medicine, 9(2), 543.
https://doi.org/10.3390/jcm9020543